Fig. 5

MT inhibits pyroptosis through the SIRT3/FOXO3α/ROS axis. (A) q-RT‒PCR analysis of FOXO3α, SIRT3 and mnSOD after the different treatments. (B) FOXO3α interference segment selection. (C) q-RT‒PCR analysis of FOXO3α, SIRT3 and mnSOD after the different treatments. (D) ELISA determination of 4-HNE secretion. (E) Quantification of catalase activity (colorimetric detection). (F) WB analysis of the expression of 4-HNE and catalase in macrophages. (G) WB analysis of the protein expression of FOXO3α, SIRT3, and mnSOD in macrophages. (H) DCFH-DA staining to detect ROS levels in cells after the different treatments (scale bar: 100 μm). (I) MitoSOX Red Mitochondrial Superoxide Indicator staining to detect mitochondrial ROS levels after the different treatments (scale bar: 100 μm). Data are presented as mean ± SD (n = 3 represents three independent experiments per group); ^*P < 0.05, ^**P < 0.01, and ^***P < 0.001 vs. control cells. ^#P < 0.05, ^##P < 0.01, and ^###P < 0.001 vs. nicotine-treated cells